New combo aims to prevent lymphoma relapse after transplant or CAR-T
NCT ID NCT06242834
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 24 times
Summary
This study tests whether adding two drugs—pembrolizumab and tazemetostat—after standard stem cell transplant or CAR-T cell therapy can help prevent aggressive B-cell lymphoma from coming back. About 32 adults who have already had or are about to have one of these treatments will receive the drug combination. The goal is to see if this approach improves the chance of staying cancer-free longer than current standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.